Sancilio Pharmaceuticals

General Information

We are a fully integrated specialty pharmaceutical company focused on developing and, in the future, commercializing products based on our proprietary Advanced Lipid Technologies, or ALT, platform. We intend to utilize our current manufacturing facility to manufacture our proprietary product candidates, if approved. ALT is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients, or APIs. Lipids are small hydrophobic or amphipathic molecules, including fatty acids (such as omega-3 fatty acids and omega-6 fatty acids), steroids, hormones and fat-soluble vitamins (such as vitamins A, D, E and K). Our business model is to apply our ALT platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases that result from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT platform, we make use of and license rights to our proprietary ALT platform and our other technologies to third parties as part of our development and manufacture of lipophilic API-based and soft-gelatin products at our facilities.

Employees: 183
Founded: 2012
Contact Information
Address 2129 N. Congress Avenue, Riviera Beach, FL 33404, US
Phone Number (561) 847-2302
Web Address
View Prospectus: Sancilio Pharmaceuticals
Financial Information
Market Cap
Revenues $24.8 mil (last 12 months)
Net Income $-4.2 mil (last 12 months)
IPO Profile
Symbol SPCI
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $86.3 mil
Manager / Joint Managers UBS Investment Bank/ Piper Jaffray
CO-Managers JMP Securities/ FBR
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change